Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.

Abstract

BACKGROUND:

Antiplatelet therapy with aspirin and antithrombotic therapy with heparin both prevent the complications of unstable angina; however, no definitive data exist on the relative clinical efficacy of the two drugs.

METHODS AND RESULTS:

Aspirin (325 mg bid) or heparin (5000-U intravenous bolus followed by a perfusion titrated to the APTT) were compared in a double-blind randomized trial of 484 patients in two cohorts enrolled sequentially. The study was initiated at admission to hospital at a mean of 8.3 +/- 7.8 hours after the last episode of pain. End points were assessed 5.7 +/- 3.3 days later, when the decision for long-term management was made. Myocardial infarction occurred in 2 (0.8%) of the 240 patients randomized to heparin and in 9 (3.7%) of the 244 randomized to aspirin (P = .035), an odds ratio of 0.22 and a risk difference of 2.9% (95% confidence limits, 0.3% to 5.6%) with heparin. The only death resulted from a myocardial infarction in an aspirin patient. Survival curves with Cox logistic regression analysis showed that the improvement in survival without myocardial infarction with heparin (P = .035) was independent of other baseline characteristics.

CONCLUSIONS:

This study documents that heparin prevents myocardial infarction better than aspirin during the acute phase of unstable angina.

• Authors: P Théroux, D Waters, S Qiu, J McCans, P de Guise, M Juneau
• Journal: Circulation (Circulation) Vol. 88 Issue 5 Pt 1 Pg. 2045-8 (Nov 1993) ISSN: 0009-7322 [Print] United States
• PMID: 8222097 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Heparin
• Aspirin

Topics

• Acute Disease
• Angina, Unstable (complications, drug therapy)
• Aspirin (therapeutic use)
• Double-Blind Method
• Drug Therapy, Combination
• Factor Analysis, Statistical
• Female
• Heparin (therapeutic use)
• Humans
• Male
• Middle Aged
• Myocardial Infarction (etiology, prevention & control)